NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis $0.70 -0.02 (-2.79%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.67▼$0.7250-Day Range$0.49▼$0.7652-Week Range$0.43▼$1.38Volume74,630 shsAverage Volume174,107 shsMarket Capitalization$57.88 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get VolitionRx alerts: Email Address VolitionRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside258.2% Upside$2.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingAcquiring Shares$100,500 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector675th out of 910 stocksDiagnostic Substances Industry8th out of 14 stocks 3.3 Analyst's Opinion Consensus RatingVolitionRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVolitionRx has only been the subject of 1 research reports in the past 90 days.Read more about VolitionRx's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VNRX. Previous Next 0.0 Dividend Strength Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VNRX. Previous Next 2.4 News and Social Media Coverage News SentimentVolitionRx has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for VolitionRx this week, compared to 0 articles on an average week.MarketBeat Follows3 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.80% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.09% of the stock of VolitionRx is held by institutions.Read more about VolitionRx's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About VolitionRx Stock (NYSE:VNRX)VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More VNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNRX Stock News HeadlinesAugust 22, 2024 | insidertrades.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 150,000 Shares of StockSeptember 2, 2024 | americanbankingnews.comVolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.comSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 28, 2024 | americanbankingnews.comVolitionRx (NYSE:VNRX) Now Covered by StockNews.comAugust 28, 2024 | americanbankingnews.comStockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)August 15, 2024 | seekingalpha.comVolitionRx Limited (VNRX) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | prnewswire.comVolitionRx Limited Announces Second Quarter 2024 Financial Results and Business UpdateAugust 14, 2024 | msn.comVolitionRX Q2 2024 Earnings PreviewSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 9, 2024 | prnewswire.comVolitionRx Announces Pricing of up to $21.5 Million Registered Direct OfferingAugust 6, 2024 | prnewswire.comVolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business UpdateJuly 9, 2024 | prnewswire.comVolition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensingJune 27, 2024 | prnewswire.comVolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual MeetingMay 29, 2024 | prnewswire.comVolitionRx Limited to Present at Jefferies Global Healthcare ConferenceMay 15, 2024 | finance.yahoo.comVolitionRX Ltd (VNRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and ...May 13, 2024 | washingtonpost.comVolitionRX: Q1 Earnings SnapshotMay 13, 2024 | prnewswire.comVolitionRx Limited Announces First Quarter 2024 Financial Results and Business UpdateMay 8, 2024 | prnewswire.comVolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business UpdateSee More Headlines Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNYSE:VNRX CUSIPN/A CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+258.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,320,000.00 Net Margins-3,318.42% Pretax Margin-3,355.68% Return on EquityN/A Return on Assets-165.21% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.24 Sales & Book Value Annual Sales$976,516.00 Price / Sales59.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-2.79Miscellaneous Outstanding Shares82,928,000Free Float72,313,000Market Cap$57.88 million OptionableOptionable Beta1.12 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Comp: $239.51kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Comp: $572.43kDr. Gaetan Michel Ph.D. (Age 50)Chief Operating Officer Comp: $518.15kDr. Salvatore Thomas Butera DVM (Age 72)Chief Executive Officer of Volition Veterinary Diagnostics Development LLC Comp: $477.25kMr. Terig Hughes (Age 53)CFO & Treasurer Comp: $338.74kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Comp: $571.55kMr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 52)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More ExecutivesKey Competitors2seventy bioNASDAQ:TSVTADC TherapeuticsNYSE:ADCTEliem TherapeuticsNASDAQ:ELYMProcaps GroupNASDAQ:PROCInhibrxNASDAQ:INBXView All CompetitorsInsidersGuy Archibald InnesBought 150,000 shares on 8/20/2024Total: $100,500.00 ($0.67/share)Corp Ltd EightSold 20,000 sharesTotal: $18,000.00 ($0.90/share)Salvatore Thomas ButeraBought 10,000 shares on 12/18/2023Total: $8,300.00 ($0.83/share)Corp Ltd EightSold 20,000 sharesTotal: $15,000.00 ($0.75/share)Salvatore Thomas ButeraBought 10,000 shares on 12/15/2023Total: $7,700.00 ($0.77/share)View All Insider Transactions VNRX Stock Analysis - Frequently Asked Questions How have VNRX shares performed this year? VolitionRx's stock was trading at $0.7170 at the beginning of 2024. Since then, VNRX stock has decreased by 2.7% and is now trading at $0.6979. View the best growth stocks for 2024 here. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) released its earnings results on Wednesday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm earned $0.40 million during the quarter, compared to analysts' expectations of $0.34 million. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VNRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
